Resources

Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease

Subscribe to Our Email List

Consent

Talk to Our Experts

Whether you are looking to learn more about our platforms or get a project started, contact our team today to discover how ProtaGene can support your development programs.

Contact Us